Aldosterone causes tissue inflammation leading to fibrosis and remodeling in the heart, vasculature, and kidney. We summarize recent data regarding the mechanism(s) through which aldosterone stimulates inflammation.
Introduction
Aldosterone binds to the mineralocorticoid receptor of principal cells in the collecting duct of the kidney, stimulates expression of genes such as serum-inducible and glucocorticoid-inducible kinase 1 (SGK1), and activates the epithelial sodium channel (ENaC) to regulate salt excretion, extracellular volume, and blood pressure. Aldosterone can exert effects in nonepithelial cells such as cardiomyocytes, endothelial cells, vascular smooth muscle cells (VSMCs), mesangial cells, and podocytes via the mineralocorticoid receptor and subsequent genomic events, as well as through nongenomic pathways. Cortisol also binds the mineralocorticoid receptor with high affinity. In epithelial tissues, the enzyme 11bhydroxysteroid dehydrogenase type 2 (11bHSD-2) converts cortisol (or corticosterone in rodents) to cortisone, which does not bind the mineralocorticoid receptor. Many nonepithelial cells lack 11bHSD-2 and, thus, cortisol occupies the mineralocorticoid receptor of these cells. Studies conducted over the past 15 years reveal that aldosterone causes inflammation leading to fibrosis and remodeling in the heart, vasculature, and kidney.
Here we review recent developments in our understanding of the mechanism(s) through which aldosterone stimulates inflammation.
Aldosterone induces inflammation by stimulating the formation of reactive oxygen species
The generation of reactive oxygen species (ROS) such as superoxide and hydrogen peroxide triggers activation of proinflammatory transcription factors activator protein (AP)-1 and nuclear factor (NF)-kB. Systemic administration of aldosterone increases nicotinamide adenine dinucleotide phosphate [NADP(H)] oxidase and oxidative stress in macrophages, the heart, vasculature, and kidneys [1] [2] [3] [4] . Aldosterone also decreases the expression of glucose-6-phosphate dehydrogenase (G6PD), which reduces NADPþ to NADPH [5]. Exogenous aldosterone stimulates aortic expression of NOX2 (also known as gp91phox) and p22phox through a mineralocorticoid receptor-dependent mechanism and of p47phox mRNA through both AT 1 receptor and mineralocorticoid receptor-dependent mechanisms [3] . Mineralocorticoid receptor activation contributes to angiotensin II (Ang II)-mediated activation of NADPH oxidase in the heart and aorta [6] [7] [8] . Aldosterone stimulates activation of NF-kB in the heart, an effect that is prevented in NOX 2-deficient mice [7] . Conversely, antioxidant drugs [1,3,9-11] decrease inflammation and injury in aldosterone-treated rodents.
Activation of NF-kB by aldosterone further induces the production of adhesion molecules, chemokines such as monocyte chemoattractant protein (MCP-1), and inflammatory cytokines. In-vitro aldosterone upregulates the lymphocyte chemoattractant factor IL-16, cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and type I and type III collagens in human VSMCs [12] . Physiologic concentrations of aldosterone induce rapid increases in expression of genes involved in inflammation and fibrosis, including orosomucoid-1 (orm-1), plasminogen activator inhibitor-1 (PAI-1), and tenascin-X in mineralocorticoid receptor-expressing cardiomyocytes, and PAI-1 in monocytes, mesangial cells, endothelial cells, and VSMCs [13] [14] [15] [16] .
In vivo, treatment of rats with aldosterone and salt increases the expression of intercellular adhesion molecule (ICAM), cyclooxygenase (COX)-2, osteopontin, and MCP-1 in the heart and causes inflammatory arterial lesions with perivascular macrophages [17] . Mineralocorticoid receptor blockade decreases this inflammatory response. Aldosterone/salt treatment also causes mineralocorticoid receptor-dependent perivascular leukocyte infiltration and increased expression of osteopontin, MCP-1, IL-6, and IL-1b in the kidney [18] . Mineralocorticoid receptor antagonism decreases aortic inflammation, fibrosis, and hypertrophy in hypertensive rats [19] [20] [21] and decreases oxidative stress and inflammation in apolipoprotein E-deficient mice fed a high-cholesterol diet, a model of atherosclerosis [22] .
Endothelial mineralocorticoid receptor regulates inflammatory cell infiltration and adhesion
In addition to stimulating the formation of ROS, aldosterone may promote vascular inflammation by stimulating endothelial exocytosis and adhesion. Endothelial cells express functional mineralocorticoid receptor as well as 11bHSD-2 [23] . Aldosterone stimulates endothelial expression of ICAM-1 and promotes the adhesion of leukocytes to endothelial cells [23] . Jeong et al. [24 ] demonstrated that physiological aldosterone stimulates the release of von Willebrand factor and IL-18, but not tissue plasminogen activator (t-PA), from human aortic endothelial cells. At the same time, aldosterone enhanced the adherence of leukocytes to endothelial cells through a P-selectin-dependent mechanism. The group further demonstrated that aldosterone stimulates endothelial exocytosis through a nongenomic, but mineralocorticoid receptor-dependent mechanism. That is, aldosterone stimulated endothelial exocytosis within 10 min and exocytosis was not blocked by actinomycin. Either spironolactone or antimineralocorticoid receptor small interfering RNA (siRNA) blocked aldosterone-stimulated exocytosis.
Neutrophils also express mineralocorticoid receptor and 11bHSD-2. In neutrophils cultured on fibronectin, aldosterone inhibits the activation of NF-kB by IL-8 or granulocyte colony-stimulating factor, decreases expression of ICAM-1, and prevents adhesion through a mineralocorticoid receptor-dependent mechanism [25 ] . Aldosterone does not affect lipopolysaccharidestimulated activation of NF-kB in neutrophils on fibronectin. Thus, the mineralocorticoid receptor-dependent proinflammatory effects of aldosterone depend on the stimulus and target cell.
Aldosterone promotes inflammation via mineralocorticoid receptor-dependent and mineralocorticoid receptor-independent mechanisms
Activation of the mineralocorticoid receptor by aldosterone results in its dissociation from molecular chaperones, translocation into the nucleus, and binding to hormone response elements in the regulatory region of target gene promoters to enhance expression. As noted earlier, aldosterone can also exert rapid, nongenomic effects. Data are conflicting as to whether or not these rapid effects occur via mineralocorticoid receptor activation. For example, some rapid effects of aldosterone cannot be blocked by the mineralocorticoid receptor antagonist spironolactone, but may be blocked by its open-ring water-soluble metabolite, canrenoate, or by eplerenone [26, 27] . Studies on fibroblasts derived from mineralocorticoid receptor-deficient mice and on mineralocorticoid receptor-transfected human embryonic kidney (HEK) cells suggest that the mineralocorticoid receptor contributes to the nongenomic effects of aldosterone on the extracellular signal-regulated kinases 1 and 2 (ERK1/2) and c-Jun NH 2 -terminal kinase (JNK) pathway, but not to rapid effects on calcium [28, 29] . In rabbit heart, aldosterone increases Na þ /K þ /2Clco-transporter activity and decreases Na þ /K þ pump activity through a nongenomic effect on protein kinase C-epsilon (PKCe) [30] , which stimulates NF-kB activation via mitogenactivated protein kinase (MAPK)s [31] . In addition, nongenomic effects of aldosterone may facilitate classical mineralocorticoid receptor-mediated effects.
In VSMCs, phosphorylation or activation of p38, MAPKs, and ERK1/2 results in the production of cytokines and chemokines [32] . Aldosterone rapidly activates ERK1/2 in VSMCs [33] . Aldosterone also enhances both the rapid and the delayed activation of ERK1/2 by Ang II. The mineralocorticoid receptor blocker, spironolactone, does not block rapid phosphorylation of ERK1/2 by aldosterone [34] . In contrast, spironolactone or inhibitors of transcription and protein synthesis prevent the late effect of aldosterone and Ang II. The early phase involves the transactivation of the epidermal growth factor receptor (EGFR), whereas the late phase involves increased expression of the fibrotic and proliferative small and monomeric GTP-binding protein Ki-ras2A and MAPK [33] . In human aortic smooth muscle cells, aldosterone induces EGFR expression via an interaction between the ligand-bound mineralocorticoid receptor and regions 316-163 and 163-1 bp of the EGFR promoter [35] .
Crosstalk between AT 1 receptor and mineralocorticoid receptor in vascular smooth muscle cells involved in stimulation of proinflammatory pathways
Just as aldosterone enhances the effects of AT 1 activation, Ang II activates mineralocorticoid receptor responsive elements through an AT 1 -dependent mechanism in human coronary artery smooth muscle cells [12]. Lemarie et al. [36 ] have further characterized the interactive effects of the AT 1 and mineralocorticoid receptors by studying the effect of Ang II or aldosterone in mouse VSMCs transfected with siRNA targeting AT 1a , AT 1b , or mineralocorticoid receptor or a negative control siRNA.
(The mouse has two AT 1 receptors, AT 1a and AT 1b .) AT 1a receptor knockdown prevented aldosterone-induced phosphorylation of the proinflammatory ERK1/2, JNK, and NF-kB, as well as c-fos expression. Knockdown of the AT 1b receptor also decreased aldosterone-induced activation of NF-kB, but did not affect phosphorylation of ERK1/2 or JNK. Mineralocorticoid receptor knockdown abolished activation and nuclear translocation of NF-kB in response to either Ang II or aldosterone. In contrast, mineralocorticoid receptor knockdown did not prevent Ang II-induced or aldosterone-induced phosphorylation of ERK1/2 or JNK. The mineralocorticoid receptor antagonist eplerenone decreased phosphorylation of JNK in response to aldosterone and activation of NF-kB in response to either Ang II or aldosterone. Taken together, these data suggest that activation of NF-kB by either Ang II or aldosterone requires both the AT 1 receptor and the mineralocorticoid receptor. Ang II can induce activation of ERK1/2 or JNK through AT 1 , in the absence of the mineralocorticoid receptor. Aldosterone also stimulates activation of ERK1/2 through an AT 1 -dependent, mineralocorticoid receptor-independent mechanism, but may require both AT 1 and mineralocorticoid receptor to activate JNK. Given that activation of ERK1/2 and JNK promotes vascular inflammation, these data suggest that AT 1 receptor blockers and mineralocorticoid receptor antagonists could have synergistic anti-inflammatory effects.
Cell-specific proinflammatory effects of aldosterone in kidney and retina
Studies by Leroy et al. [37 ] provide an interesting link between the proinflammatory and profibrotic effects of aldosterone in nonepithelial cells to the classic physiologic role of aldosterone in promoting epithelial sodium transport. The investigators demonstrated that aldosterone activates the canonical NF-kB pathway and stimulates the expression of proinflammatory genes in principal cells, the site of mineralocorticoid receptor-mediated effects of aldosterone on sodium reabsorption and potassium excretion. In the principal cell, aldosterone stimulates NF-kB via a mineralocorticoid receptor-dependent increase in SGK1 expression rather than via ERK or p38. Interestingly, activation of NF-kB by lipopolysaccharide (LPS) decreases SGK1 expression, activity of the ENaC a-subunit, and glucocorticoid-stimulated and mineralocorticoid-stimulated sodium transport in cultured principal cells [38] as well as amiloride-sensitive ion fluxes in cortical collecting duct cells [39] . Increased expression of the NF-kB target gene PAI-1 could also decrease activation of ENaC by decreasing plasmin-mediated proteolytic cleavage of its g-subunit [40] . These data suggest that the proinflammatory effects of aldosterone may serve to modulate the effects of aldosterone on salt reabsorption.
Hypertension affects the microvasculature of the kidney and retina through many common mechanisms. Wilkinson-Berka et al. [41 ] investigated the contribution of aldosterone and mineralocorticoid receptor activation to pathological angiogenesis in rats with oxygen-induced retinopathy. The authors identified aldosterone synthase, a functional mineralocorticoid receptor, and 11bHSD-2 in the retina. Spironolactone reduced angiogenesis in this model. Treatment of rats with aldosterone and high-salt intake caused increased leukocyte infiltration and angiogenesis in the retina, as well as increased retinal expression of NOX4 and MCP-1 and decreased retinal expression of G6PD. High salt alone also increased inflammation and angiogenesis and this effect was prevented by mineralocorticoid receptor antagonism. As inflammation leads to retinal vascular growth [42] , these studies suggest that mineralocorticoid receptor antagonism could be effective in the prevention of diabetic retinopathy. Further studies are needed to assess the effect of mineralocorticoid receptor antagonism on retinopathy in patients with diabetes.
A key role for macrophage in aldosteroneinduced oxidative stress and remodeling
Two recent studies highlight the critical role of the macrophage in aldosterone-induced inflammation. In the first, Leibovitz et al. [43 ] reported that mice with reduced monocyte/macrophage-induced inflammation resulting from a mutation in the gene encoding macrophage-colony stimulating factor are protected from aldosterone/salt-induced oxidative stress and endothelial dysfunction. Aortic collagen content was also decreased in monocyte/macrophage-impaired mice relative to wild-type. Aldosterone increased IL-6 and IL-10 concentrations in monocyte/macrophage-impaired mice, suggesting that these cytokines can originate from T-lymphocytes in the absence of increased oxidative stress. Monocyte/macrophage-impaired mice were not protected against aldosterone/salt-induced arterial fibronectin deposition or arterial stiffness.
Rickard et al. [44 ] reported on the effect of macrophagespecific deletion of the mineralocorticoid receptor on inflammation in mice that were treated with the mineralocorticoid deoxycorticosterone (DOC) for 8 days, 4, or 8 weeks. At 8 days, MCP-1 concentrations and macrophage infiltration in the heart were similar in wild-type and macrophage-specific mineralocorticoid receptor-knockout mice, whereas DOC/salt-induced NOX2 and PAI-1 expression was decreased. Blood pressure was lower in the macrophage-specific mineralocorticoid receptorknockout mice at 4 and 8 weeks. Despite having lower blood pressure, the macrophage-specific mineralocorticoid receptor-knockout mice were not protected against cardiac hypertrophy and seemed to have renal hypertrophy even in the absence of DOC/salt. DOC/salt-induced interstitial and perivascular collagen deposition were reduced in the macrophage-specific mineralocorticoid receptor knockouts compared to wild-type at 8 weeks. In short, macrophage-specific mineralocorticoid receptorknockout mice were protected against fibrosis and hypertension, even though there was no change in macrophage infiltration.
This study has several important implications. First, the study confirms that the macrophage mineralocorticoid receptor does not control macrophage infiltration, consistent with the reports by Caprio et al. [23] and Jeong et al. [24 ] that indicate that endothelial cell mineralocorticoid receptor promotes macrophage adhesion and infiltration. Second, the study adds a new dimension to the emerging understanding that inflammation contributes to the pathogenesis of hypertension. Guzik et al. [45] and Madhur et al. [46 ] have demonstrated that T cells, and T helper (Th)-17 cells in particular, are requisite for the generation of Ang II-induced or DOCA/salt-induced hypertension. IL-17 stimulates macrophages and other cells to produce cytokines and induces remodeling. Deletion of the mineralocorticoid receptor on macrophages may disrupt this process.
Third, the study may help resolve apparently conflicting data based on a cardiomyocyte-centric view of fibrosis. Cardiomyocytes, like macrophages, lack 11bHSD-2. For this reason, under physiological conditions, cardiac mineralocorticoid receptors are occupied by cortisol or corticosterone. Cardiomyocyte-specific overexpression of 11bHSD-2 causes fibrosis [47] . Pharmacological mineralocorticoid receptor antagonism prevents cardiac fibrosis in this model, leading some to suggest that endogenous cortisol acts as an antagonist at the cardiomyocyte mineralocorticoid receptor. Cardiomyocyte-specific mineralocorticoid receptor deletion does not alter fibrosis in this model, however [48] . It would be interesting to know whether macrophage-specific deletion of the mineralocorticoid receptor protected 11bHSD-2 transgenics from hypertrophy.
Aldosterone contributes to inflammation in obesity
Aldosterone concentrations correlate with body mass index. Increased ROS and inflammation due to mineralocorticoid receptor activation may contribute to insulin resistance in obesity [49] . Treatment of cultured adipocytes with aldosterone increases expression of IL-6, PAI-1, chemerin, and leptin [50 ] . In contrast, treatment of adipocytes with the glucocorticoid receptor-specific agonist dexamethasone inhibits the expression of IL-6, MCP-1, tumor necrosis factor-a, chemerin, and leptin. In addition, in adipocytes in which the glucocorticoid receptor was knocked down or out, corticosterone increased the gene expression IL-6 and MCP-1, indicating that glucocorticoid receptor activation opposes the proinflammatory effects of mineralocorticoid receptor activation. Mineralocorticoid receptor expression is increased in the adipocytes of obese mice. Mineralocorticoid receptor antagonism decreases the production of ROS, inflammatory gene expression, and macrophage infiltration in adipose tissues and reduces insulin resistance in obese mice [51 ,52] .
Aldosterone synthase inhibitors decrease inflammation in rodent models
Mineralocorticoid receptor antagonists prevent the inflammatory effects of aldosterone in most rodent models. Aldosterone synthase inhibitors are also under development. However, as mineralocorticoid receptor can be activated by ligands other than aldosterone, it does not necessarily follow that reducing aldosterone concentrations will reduce inflammation. Conversely, reducing aldosterone may offer advantages as mineralocorticoid receptor antagonism does not block some rapid proinflammatory effects of aldosterone and even promotes activation of NF-kB in neutrophils. Studies on aldosterone synthase-deficient mice have begun to reveal tissue-specific contributions of endogenous aldosterone proinflammatory gene expression [53 ] . Pharmacological aldosterone synthase inhibition decreases cardiac and renal injury to the same extent as mineralocorticoid receptor antagonism [54, 55 ] . Inhibition of aldosterone synthase in the brain also decreases blood pressure [56 ] . The specificity of pharmacological inhibitors for aldosterone synthase, the enzyme responsible for the final step in the synthesis of aldosterone, versus 11b-hydroxylase, the enzyme responsible for the final step in the synthesis of cortisol, may be a challenge for drug development [57 ] . Aldosterone synthase inhibitors are under investigation for the treatment of hyperaldosteronism but could prevent end-organ damage in essential hypertension.
Conclusion
Studies published in the last year have elucidated cellspecific mineralocorticoid receptor-dependent effects of aldosterone on cell adhesion and cytokine expression, as well as on renal function. The macrophage plays a central role in mineralocorticoid-induced vascular and cardiac fibrosis. Aldosterone contributes to the inflammatory phenotype of obesity and the induction of ROS by aldosterone also contributes to insulin resistance. Aldosterone synthase inhibitors, like mineralocorticoid receptor antagonists, reduce inflammation. Inflammation contributes to vascular, cardiac, and renal injury. Ongoing and future clinical trials will reveal the extent to which preventing the proinflammatory effects of aldosterone reduces endorgan damage.
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